In cancer pt of breast pt complain of kan bajana kan bhari rehna what medication and at what dose to be given and cause of it
Reading File
Searching the Web
breast cancer chemotherapy tinnitus ear fullness ototoxicity cisplatin treatment management
Finding Sources
Finding Sources
Searching PubMed
cisplatin ototoxicity tinnitus treatment management
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Now I have enough information from authoritative textbook sources and web data to give a full answer. Here is the complete clinical response:
Breast Cancer Patient - "Kan Bajana" & "Kan Bhari Rehna" (Tinnitus + Ear Fullness)
DIAGNOSIS: Chemotherapy-Induced Ototoxicity
The patient's complaints directly translate to:
- Kan bajana = Tinnitus (ringing/buzzing in ears)
- Kan bhari rehna = Aural fullness / ear blockage sensation
These are classic features of drug-induced cochlear damage, most commonly from chemotherapy agents used in oncology.
CAUSE (Etiology)
Primary Culprits in Breast Cancer:
| Drug | Ototoxicity Risk | Notes |
|---|---|---|
| Cisplatin | Very High | Most ototoxic; dose-dependent, cumulative, often irreversible |
| Carboplatin | Moderate | Less ototoxic than cisplatin but risk increases at high doses |
| Taxanes (paclitaxel, docetaxel) | Moderate | Recently confirmed as cochleotoxic; commonly used in breast cancer |
"Ototoxicity caused by cisplatin is unaffected by diuresis and is manifested by tinnitus and high-frequency hearing loss." - Goodman & Gilman's Pharmacological Basis of Therapeutics
"SNHL is seen in more than 50% of patients and tinnitus is seen in 7% [with platinum-based agents]." - KJ Lee's Essential Otolaryngology
Mechanism of Ototoxicity:
- Cisplatin accumulates in the cochlea (specifically stria vascularis and outer hair cells)
- Generates reactive oxygen species (ROS) causing oxidative damage
- Destroys outer hair cells of the organ of Corti, especially at basal turn (high-frequency region 4,000-8,000 Hz)
- Also causes inappropriate gene activation leading to cochlear cell death
- Damage is bilateral, symmetric, and often permanent
Risk Factors that worsen ototoxicity:
- Cumulative dose >400 mg/m² of cisplatin
- Age (elderly or very young)
- Concurrent cranial irradiation
- Combination with other ototoxic drugs (aminoglycosides, loop diuretics)
- Renal insufficiency (impaired drug elimination)
- Nutritional depletion and anemia
MANAGEMENT & MEDICATIONS
Step 1 - STOP or REDUCE the offending drug
- First action: Inform oncologist immediately
- Consider dose reduction or switching from cisplatin to carboplatin (less ototoxic)
- If ototoxicity is severe (speech-frequency involvement), chemotherapy adjustment is mandatory
Step 2 - Protective/Preventive Agents
| Agent | Dose | Evidence | Notes |
|---|---|---|---|
| Sodium Thiosulfate (STS) | 16 g/m² IV over 15 min, given 6 hrs after cisplatin | Strong (RCT, FDA-approved 2022) | FDA-approved for pediatric patients; being studied in adults. Binds free platinum before it reaches cochlea |
| Amifostine | 910 mg/m² IV before cisplatin | Moderate | Cytoprotective thiophosphate; primarily reduces nephrotoxicity; limited ototoxicity data in adults |
| Vitamin E (alpha-tocopherol) | 400 IU orally twice daily | Moderate (RCT) | Antioxidant; shown to significantly protect hearing at 2 kHz and 8 kHz in cisplatin-treated patients |
| N-Acetylcysteine (NAC) | 825 mg/m² IV | Investigational | Antioxidant; under study |
"Amifostine, a thiophosphate cytoprotective agent, reduces renal toxicity associated with repeated administration of cisplatin. Ototoxicity caused by cisplatin is unaffected by diuresis." - Goodman & Gilman's
Step 3 - Symptomatic Treatment of Tinnitus
For active tinnitus and aural fullness:
| Medication | Dose | Role |
|---|---|---|
| Betahistine | 16 mg 3 times/day (or 24 mg twice daily) | Improves cochlear microcirculation; H1 agonist/H3 antagonist; reduces aural fullness and tinnitus |
| Cinnarizine | 25 mg 3 times/day | Calcium channel blocker; improves inner ear blood flow; helps with ear fullness and vertigo |
| Flunarizine | 5-10 mg at bedtime | Calcium channel blocker; useful if vertigo is also present |
| Magnesium supplementation | Mg gluconate/oxide 500 mg/day | Cisplatin causes hypomagnesemia which worsens cochlear damage - must be corrected |
| Clonazepam | 0.25-0.5 mg at bedtime | For severe tinnitus causing sleep disturbance |
| Melatonin | 3 mg at bedtime | Antioxidant; some evidence for tinnitus relief |
Step 4 - Electrolyte Correction (Very Important!)
Cisplatin commonly causes:
- Hypomagnesemia - replace with Mg sulfate or oral Mg preparations
- Hypokalemia - replace with KCl
- Hypocalcemia
These electrolyte imbalances directly worsen cochlear function and tinnitus.
"Electrolyte disturbances, including hypomagnesemia, hypocalcemia, hypokalemia, and hypophosphatemia, are common... Routine measurement of Mg²⁺ concentrations in plasma is recommended." - Goodman & Gilman's
Step 5 - Audiology Referral
- Baseline and serial audiograms (pure tone + ultra-high frequency)
- Monitor at 4 kHz, 8 kHz specifically (earliest affected)
- If speech frequencies involved: refer for hearing aid assessment
SUMMARY BOX
Kan bajana + Kan bhari rehna in cancer patient
↓
Chemotherapy-induced ototoxicity
(Cisplatin / Carboplatin / Taxane)
↓
IMMEDIATE:
1. Report to oncologist - dose adjustment
2. Correct Mg, K, Ca levels
3. Audiogram
PROTECTIVE:
- Sodium thiosulfate / Amifostine / Vitamin E
SYMPTOMATIC:
- Betahistine 16 mg TDS
- Cinnarizine 25 mg TDS
- Magnesium supplementation
- Clonazepam if sleep disturbed
Key Point: Cisplatin ototoxicity is largely irreversible - therefore early detection (serial audiograms), prompt dose modification, and antioxidant/protective strategies started before or during chemotherapy are far more effective than trying to treat established hearing loss. Prevention is the priority.
Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics; Cummings Otolaryngology; KJ Lee's Essential Otolaryngology; Adams & Victor's Principles of Neurology; Oncology Nurse Advisor review; Breast Cancer Org study 2022
This is a shared conversation. Sign in to Orris to start your own chat.